Related Experiment Video
Updated: Dec 21, 2025
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.3K
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
Yi-Ling Ko1, Kazuhide Takata1, Takashi Tanaka1
1Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Case Reports in Gastroenterology
|May 14, 2020
Summary
Ectopic hepatocellular carcinoma (HCC), a rare cancer outside the liver, was diagnosed in a 73-year-old male. Treatment with sorafenib showed limited efficacy, highlighting the need for further research into effective therapies for this condition.
Area of Science:
- Oncology
- Gastroenterology
Background:
- Ectopic hepatocellular carcinoma (HCC) is an exceptionally rare malignancy.
- It shares morphological and immunohistochemical similarities with intrahepatic HCC.
Observation:
- A 73-year-old male presented with abdominal pain and peritoneal nodules on CT scan.
- Diagnostic laparoscopy confirmed ectopic HCC.
- Elevated serum alpha-fetoprotein and PIVKA-II levels supported the diagnosis.
Findings:
- The patient received sorafenib for unresectable ectopic HCC.
- Tumor progression occurred despite treatment, leading to cessation of sorafenib due to complications.
- Tumor progression and death occurred within one year of diagnosis.
Implications:
- The optimal treatment for unresectable ectopic HCC remains undetermined.
- Accumulating more cases is crucial to evaluate the efficacy of tyrosine kinase inhibitors (TKIs) in ectopic HCC.
